Table 2. Single agent phase II studies with gefitinib and erlotinib in NSCLC pts.
| Trial | Agent | No. of pts | Median OS (months) | RR (%) | Toxicities (%) | Comments |
|---|---|---|---|---|---|---|
| Perez-Soler | Erlotinib 150 mg/d | 57 | 8.4 | 12.3 | Rash 75; diarrhea 56 | Single arm, EGFR + prior platinum |
| IDEAL 1 | Gefitinib | 210 | Rash 59.2 vs. 82.9; diarrhea 39.8 vs. 57.6 | Random, double-blind, prior platinum | ||
| 250 mg/d | 7.6 | 18.4 | ||||
| 500 mg/d | 8 | 19 | ||||
| IDEAL 2 | Gefitinib | 221 | Rash 62 vs. 75; diarrhea 57 vs. 75 | Random, double-blind, prior platinum | ||
| 250 mg/d | 7 | 12 | ||||
| 500 mg/d | 6 | 9 |
NSCLC, non-small cell lung cancer.